Remarkable response to Rituximab in a 72-year-old patient with refractory non-Hodgkin's lymphoma and marrow aplasia

• Verfasst von: Egerer, Gerlinde [VerfasserIn]
• Verfasst von: Sauerland, Katrin [VerfasserIn]
• Verfasst von: Ho, Anthony Dick [VerfasserIn]
• Titel: Remarkable response to Rituximab in a 72-year-old patient with refractory non-Hodgkin's lymphoma and marrow aplasia
• Verf.angabe: G. Egerer, K. Sauerland & A.D. Ho (Department of Internal Medicine V, Hematology, Oncology and Rheumatology, Universityof Heidelberg)
• E-Jahr: 2001
• Jahr: [2001]
• Umfang: 3 S.
• Illustrationen: 1 Diagramm
• Fussnoten: Elektronische Reproduktion der Druckausgabe ; Gesehen am 21.12.2021
• Titel Quelle: Enthalten in: Leukemia and lymphoma
• Ort Quelle: London [u.a.] : Taylor & Francis Group, 1989
• Jahr Quelle: 2001
• Band/Heft Quelle: 42(2001), 3, Seite 551-553
• ISSN Quelle: 1029-2403
• DOI: doi:10.3109/10428190109064616
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: bone marrow aplasia
• Sach-SW: non-Hodgkin's lymphoma
• Sach-SW: Rituximab
• K10plus-PPN: 1782638938

Abstract

The chimeric human mouse antibody rituximab represents a substantial advance over the use of unmodified murine antibodies. Multicenter trials showed that rituximab induced remission in 48% of 166 relapsed lymphoma patients with minimal toxicity. Thus, the antibody might play a role in patients who cannot tolerate chemotherapy because of marrow aplasia. We observed a continuous complete remission induced by rituximab alone in a 72 year old patients with refractory and progressive high-grade non-Hodgkin's lymphoma (NHL) in the phase of chemotherapy induced marrow aplasia.